STOCK TITAN

Yarrow Bioscience: Perceptive reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. common-stock ownership was reported by Perceptive Advisors LLC, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., each with shared voting and dispositive power over 1,600,647 shares, or 9.99% of the class. These are overlapping reports of beneficial ownership.

The reported percentages are based on 15,234,944 shares outstanding as of November 3, 2026, and assume exercise of pre-funded warrants for 787,549 shares. The Master Fund directly holds 813,098 common shares and 967,361 pre-funded warrants, immediately exercisable at $0.0001 per share subject to a 9.99% Beneficial Ownership Limitation. Under that limit, the reporting persons may exercise warrants for an aggregate of no more than 787,549 shares.

Beneficial ownership 1,600,647 shares Reported by each reporting person with shared voting and dispositive power
Ownership percentage 9.99% Reported for each reporting person
Common shares outstanding 15,234,944 shares As of November 3, 2026
Common shares directly held 813,098 shares Held directly by the Master Fund
Pre-funded warrants held 967,361 warrants Held directly by the Master Fund
Warrant shares permitted for exercise 787,549 shares Aggregate amount permitted under the Beneficial Ownership Limitation
Warrant exercise price $0.0001 per share Pre-funded warrants held by the Master Fund
Beneficial Ownership Limitation regulatory
"subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Pre-Funded Warrants technical
"the Pre-Funded Warrants may not be exercised"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
beneficially own regulatory
"may be deemed to beneficially own such shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared dispositive power regulatory
"Shared Dispositive Power 1,600,647.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YARW shares did the reporting persons report as beneficially owned?

Each of the three reporting persons reported beneficial ownership of 1,600,647 shares, equal to 9.99% of the class, with shared voting and dispositive power over that amount.

How was the reported YARW ownership percentage calculated?

The percentages are based on 15,234,944 shares outstanding as of November 3, 2026 and assume exercise of pre-funded warrants for 787,549 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





92941V407

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:11/16/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:11/16/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:11/16/2026

Keep reading